Oct 15, 2020
Leap Therapeutics to Present Esophagogastric Cancer Data at SITC 2020 Annual Meeting
Sep 24, 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Sep 21, 2020
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Sep 09, 2020
Leap Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Aug 24, 2020
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
Aug 13, 2020
Leap Therapeutics Reports Second Quarter 2020 Financial Results
Jun 25, 2020
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Jun 22, 2020
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Jun 18, 2020
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
Jun 17, 2020
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jun 11, 2020
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
May 14, 2020
Leap Therapeutics Reports First Quarter 2020 Financial Results
Apr 23, 2020
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
Mar 16, 2020
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Jan 23, 2020
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
Jan 07, 2020
Leap Therapeutics Announces Closing of Previously Announced Equity Financing
Jan 03, 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Nov 14, 2019
Leap Therapeutics Reports Third Quarter 2019 Financial Results
Aug 09, 2019
Leap Therapeutics Reports Second Quarter 2019 Financial Results
Aug 06, 2019
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update